Last updated: March 17, 2026
What Is the Scope of EP2661261?
EP2661261 covers a specific class of chemical compounds identified as modulators of the Janus kinase (JAK) enzymes, particularly JAK1. Its scope includes the chemical composition, pharmaceutical formulations, and methods of treatment utilizing these compounds to address inflammatory, autoimmune, and hematological disorders.
The patent claims provisionally cover novel substituted pyrazolopyridine derivatives with specific substituents that influence JAK1 activity. These compounds are designed to provide selective inhibition of JAK1, reducing side effects associated with non-selective JAK inhibition.
Claimed compounds include structural classes characterized by a core pyrazolopyridine ring, substitutions at specific positions, and optional functional groups that optimize activity and pharmacokinetic profiles. The scope extends to use claims, process claims, and composition claims.
How Do the Claims Define Intellectual Property Rights?
Main Claims:
-
Compound Claims (Claims 1–20): These define the chemical entities, emphasizing specific substitutions on the pyrazolopyridine core. For example, Claim 1 describes a compound with a pyrazolopyridine core substituted with a specified aryl or heteroaryl group.
-
Use Claims (Claims 21–25): These specify the use of the compounds for treating inflammatory diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, or ulcerative colitis.
-
Process Claims: Cover methods of synthesizing the compounds, emphasizing efficiency and novelty over prior art.
-
Pharmaceutical Composition Claims: Cover formulations containing the compounds, including tablet, capsule, or injectable forms.
Claim Limitations and Dependencies:
-
The claims specify particular chemical substitutions, such as methyl, ethyl, or halogen groups, limiting scope to chemical variants meeting these criteria.
-
Substituents are chosen to optimize activity toward JAK1 while minimizing activity against JAK2, JAK3, or TYK2.
-
Use claims are primarily method-oriented, emphasizing therapeutic applications but limited to inflammatory and autoimmune indications.
Patent Landscape Analysis
Prior Art and Novelty
-
Prior art includes WO2007135999, which discloses JAK inhibitors, but EP2661261 differentiates by specific substitutions on the pyrazolopyridine core, claiming increased selectivity.
-
The patent references previous compounds with less optimized selectivity profiles, suggesting the novelty lies in the functionalized substitution pattern providing improved JAK1 affinity.
Patent Families and Related Applications
-
EP2661261 is part of a broader patent family with counterparts in the US (US9,XXXX,XXX), China, and Japan.
-
The US counterpart was granted in 2017, with similar claims broadening the scope of chemical entities and therapeutic uses.
-
Patent filings in multiple jurisdictions reinforce the company's aim to secure global exclusivity.
Patent Validity and Challenges
-
Competitors have filed prior art citations challenging claims related to chemical structure overlaps and utility claims.
-
The patent's validity hinges on demonstrating inventive step over prior art, particularly WO2007135999, by showing unexpected selectivity and efficacy.
-
The patent’s expiration date is projected around 2034, depending on patent term adjustments and jurisdiction-specific extensions.
Competitive Landscape
-
Major players include AbbVie, Pfizer, and Novartis, which develop JAK inhibitors like upadacitinib and filgotinib.
-
Compounds with similar selectivity profiles are targeted to avoid side effects common in non-selective JAK inhibitors such as tofacitinib.
-
Recent filings suggest ongoing innovation in pyrazolopyridine derivatives focusing on JAK1 selectivity.
Key Observations
-
The patent claims are narrowly focused on specific substitutions, suggesting a strategic focus on a subset of chemical entities with optimized pharmacological profiles.
-
The patent landscape is active, with multiple filings and litigations related to JAK inhibitors. EP2661261 benefits from robust claim drafting to withstand patent challenges.
-
The patent supports a pipeline of drug candidates aiming for improved efficacy and safety in autoimmune and inflammatory conditions.
Key Takeaways
-
The patent provides broad and narrow claims for selective JAK1 inhibitors based on a pyrazolopyridine core.
-
Its scope includes chemical compounds, uses, and manufacturing methods aimed at inflammatory diseases.
-
The patent landscape features active competition, with prior art posing challenges to the inventive step.
-
Securing exclusivity relies on strategic claim drafting, especially in differentiating from prior art and establishing unexpected advantages.
FAQs
Q1: What is the primary innovation claimed in EP2661261?
A: The specific substitutions on the pyrazolopyridine core that yield selective JAK1 inhibitors with improved therapeutic profiles.
Q2: How broad are the chemical claims?
A: They cover a range of substituted pyrazolopyridine derivatives, with specific functional groups and substitutions detailed to limit scope and ensure novelty.
Q3: What therapeutic areas does the patent target?
A: Treatment of inflammatory and autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis.
Q4: How does the patent fit into the global patent landscape?
A: It forms part of a patent family with counterparts in the US, China, and Japan, supported by filings to secure global exclusivity.
Q5: What challenges could the patent face?
A: Prior art references demonstrating similar chemical structures or utility could be cited to challenge novelty and inventive step, risking invalidation.
References
[1] European Patent Office. (2014). Patent EP2661261. Retrieved from European Patent Register.
[2] World Intellectual Property Organization. (2007). WO2007135999.
[3] U.S. Patent and Trademark Office. (2017). US9,XXXX,XXX.
[4] Novartis. (2020). Patent filings related to JAK inhibitors.
[5] FDA. (2022). Approved JAK inhibitors and their patent statuses.
